Aligos Therapeutics to Unveil HBV Breakthroughs at The Liver Meeting® 2025
Aligos Therapeutics, a clinical-stage biotech company specialising in liver and viral diseases, is set to make waves at The Liver Meeting® 2025. The company will present eight updates on its research, including three poster presentations on November 7, 2025, delving into various aspects of its preclinical work on hepatitis B and metabolic dysfunction-associated steatohepatitis (MASH).
Among the highlights is a poster presentation on November 7, 2025, revealing sustained reductions in HBV antigen levels in HBeAg-positive subjects after a 96-week treatment with ALG-000184. This presentation, supported by Aligos Therapeutics, was led by Professor Man-Fung Yuen, Chair and Chief of the Division of Gastroenterology and Hepatology at the University of Hong Kong.
ALG-000184, a novel Capsid Assembly Modulator (CAM), has shown potent suppression of HBV DNA in treatment-naive or currently-not-treated subjects with chronic liver disease. Two poster presentations on the same day will detail the in vitro effects of ALG-001075 on cccDNA formation, HBV DNA integration, and HBeAg binding. The company's pipeline also includes therapeutics for coronaviruses, reflecting its broad focus on liver and viral diseases.
Aligos Therapeutics, Inc. (Nasdaq: ALGS), will make one oral presentation and seven poster presentations at The Liver Meeting® 2025, updating the scientific community on its progress in treating chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses. The company's work, including the promising results of ALG-000184, is poised to contribute significantly to the field of liver and viral diseases.
